Direct-to-consumer drug price disclosure

Summary#

This bill would require that many direct-to-consumer (DTC) prescription drug and biologic advertisements include a clear statement of the product’s wholesale acquisition cost (WAC) for a 30‑day supply or a typical course of treatment. The rule would apply to drugs and biologics for which payment is available under Medicare or Medicaid, with a narrow price exemption for very low‑cost products. The goal is to give consumers basic list‑price information when they see drug ads.

• Main change: National requirement that covered DTC ads display the WAC (list price) for a 30‑day supply or typical course.
• Who it covers: Ads for prescription drugs and biologics paid for under Medicare (title XVIII) or Medicaid (title XIX) that must already show side‑effect information under FDA rules.
• Exemption: Products with a WAC under $35 for a 30‑day supply (or typical course) are exempt.
• Timing and rulemaking: The Secretary must put the requirement in place by July 1, 2026, and must issue final regulations within one year of enactment to define how price information is shown and how quickly ads must be updated when prices change.
• Enforcement: Manufacturers (or their agents) who violate the rule may face civil money penalties up to $100,000 per violation. The bill authorizes funding as needed to carry out the rule.

What it means for you#

• Consumers / Patients

  • Ads for many prescription drugs will include the drug’s WAC (list price) for a 30‑day supply or a typical course.
  • The ad may also state that the consumer’s out‑of‑pocket cost could be different depending on insurance.
  • This could help people notice high list prices earlier, but the WAC is not the same as what many patients actually pay.

• Drug manufacturers and advertisers

  • Must include the WAC in DTC ads covered by the rule and meet display/audio requirements set by HHS regulations.
  • Must update ads when the WAC changes according to timing rules that the Secretary will set.
  • Face possible penalties (up to $100,000 per violation) for noncompliance.

• Medicare and Medicaid programs

  • The rule targets drugs for which payment is available under these programs; lawmakers described this as a way to increase price transparency and potentially slow federal drug spending growth.
  • The bill allows the federal agency to use public reporting to help enforce compliance.

• Health care providers

  • Patients who see advertised WACs may ask providers about affordable alternatives or coverage; providers may need to address questions about actual out‑of‑pocket costs.

• Insurers and pharmacy benefit managers

  • The bill does not change insurer cost‑sharing rules but may increase consumer inquiries about coverage and actual costs.

Expenses#

No direct public cost estimate is included in the bill text or accompanying material.

• No publicly available information on total federal cost or savings.
• The bill authorizes “such sums as may be necessary” for implementation, which implies HHS administrative costs for rulemaking and enforcement.
• Manufacturers and advertisers will likely face compliance costs to add price information to ads and to update ads when WACs change.
• The civil penalty structure could create enforcement‑related administrative work and potential penalty collections.

Proponents' View#

The bill appears intended to increase price transparency and consumer information. Possible arguments in favour based on the bill text and findings:

• Providing WAC in ads could help consumers know a drug’s list price before they consider treatment, aiding informed decision making.
• Greater visibility of list prices may encourage price comparison and selection of lower‑cost alternatives when clinically appropriate.
• Because Medicare and Medicaid pay for many advertised drugs, more transparent advertising could reduce wasteful federal spending by reducing demand for higher‑priced products.
• The bill uses WAC because it is a statutory, manufacturer‑set list price that the bill describes as an objective and understood point in the supply chain.

Opponents' View#

The bill’s design raises several concerns and unanswered questions that could be raised by others (phrased as concerns rather than reported arguments):

• One concern is that WAC is a manufacturer list price and often does not reflect what most patients actually pay after insurance, discounts, rebates, or coupons; displaying WAC could therefore confuse consumers about true out‑of‑pocket costs.
• The bill allows an optional statement that actual consumer costs may differ, but it does not require showing typical out‑of‑pocket amounts or insurer‑specific prices (such as copays or coinsurance), so the practical usefulness of WAC for individuals is unclear.
• The rule leaves key details to HHS rulemaking (how prices must be shown across TV, radio, online, print; how quickly ads must be updated after price changes). The lack of specific standards in the statute makes implementation timing and consistency uncertain.
• Compliance and update requirements could impose costs and operational burdens on manufacturers and advertisers, especially for products with frequent price changes.
• The civil penalty amount (up to $100,000 per violation) could be significant, but the statute does not define what counts as a single violation for ongoing or multi‑platform ads, which could create enforcement complexity.